Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT

This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS \>1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.

NCT Number	NCT07448727
Lead Sponsor	University of Rome Tor Vergata
Conditions	Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma
Enrollment	25 participants
Start Date	2024-11-20
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-04